MML Investors Services LLC boosted its stake in shares of EXACT Sciences Co. (NASDAQ:EXAS) by 38.0% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 5,050 shares of the medical research company’s stock after purchasing an additional 1,391 shares during the period. MML Investors Services LLC’s holdings in EXACT Sciences were worth $399,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in EXAS. Xact Kapitalforvaltning AB raised its holdings in EXACT Sciences by 4.5% during the third quarter. Xact Kapitalforvaltning AB now owns 18,725 shares of the medical research company’s stock valued at $1,478,000 after acquiring an additional 800 shares during the period. Chicago Partners Investment Group LLC raised its holdings in EXACT Sciences by 47.6% during the third quarter. Chicago Partners Investment Group LLC now owns 3,100 shares of the medical research company’s stock valued at $191,000 after acquiring an additional 1,000 shares during the period. IFP Advisors Inc raised its holdings in EXACT Sciences by 49.4% during the third quarter. IFP Advisors Inc now owns 6,192 shares of the medical research company’s stock valued at $489,000 after acquiring an additional 2,047 shares during the period. Commonwealth Equity Services LLC raised its holdings in EXACT Sciences by 11.5% during the third quarter. Commonwealth Equity Services LLC now owns 21,273 shares of the medical research company’s stock valued at $1,678,000 after acquiring an additional 2,193 shares during the period. Finally, GSA Capital Partners LLP raised its holdings in EXACT Sciences by 30.2% during the second quarter. GSA Capital Partners LLP now owns 10,683 shares of the medical research company’s stock valued at $639,000 after acquiring an additional 2,477 shares during the period. Institutional investors own 92.25% of the company’s stock.

Shares of EXAS stock opened at $74.92 on Friday. EXACT Sciences Co. has a 12-month low of $37.36 and a 12-month high of $82.85. The company has a current ratio of 12.08, a quick ratio of 11.72 and a debt-to-equity ratio of 0.94. The stock has a market capitalization of $9.33 billion, a PE ratio of -75.68 and a beta of 1.20.

EXACT Sciences (NASDAQ:EXAS) last issued its earnings results on Tuesday, October 30th. The medical research company reported ($0.37) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.42) by $0.05. EXACT Sciences had a negative return on equity of 20.18% and a negative net margin of 35.83%. The firm had revenue of $118.29 million for the quarter, compared to analysts’ expectations of $109.33 million. During the same period in the previous year, the firm posted ($0.23) earnings per share. The business’s revenue was up 63.0% compared to the same quarter last year. As a group, analysts predict that EXACT Sciences Co. will post -1.5 EPS for the current year.

In other news, insider Graham Peter Lidgard sold 79,673 shares of EXACT Sciences stock in a transaction dated Thursday, November 1st. The stock was sold at an average price of $71.73, for a total value of $5,714,944.29. Following the sale, the insider now directly owns 124,528 shares of the company’s stock, valued at $8,932,393.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider D Scott Coward sold 2,190 shares of EXACT Sciences stock in a transaction dated Monday, October 1st. The stock was sold at an average price of $79.51, for a total value of $174,126.90. The disclosure for this sale can be found here. Insiders sold 386,968 shares of company stock worth $27,418,499 over the last ninety days. Insiders own 3.20% of the company’s stock.

A number of equities research analysts have commented on EXAS shares. BidaskClub raised EXACT Sciences from a “hold” rating to a “buy” rating in a report on Friday, August 31st. Canaccord Genuity reissued a “buy” rating and set a $65.00 price target (up from $62.00) on shares of EXACT Sciences in a report on Monday, August 13th. Craig Hallum raised their price target on EXACT Sciences from $54.00 to $74.00 and gave the company a “buy” rating in a report on Thursday, August 23rd. Jefferies Financial Group reissued a “buy” rating and set a $74.00 price target on shares of EXACT Sciences in a report on Thursday, August 23rd. Finally, BTIG Research raised their price target on EXACT Sciences to $95.00 and gave the company a “buy” rating in a report on Wednesday, August 22nd. Four investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $84.08.

WARNING: “MML Investors Services LLC Has $399,000 Position in EXACT Sciences Co. (EXAS)” was published by Watch List News and is the sole property of of Watch List News. If you are reading this article on another publication, it was stolen and reposted in violation of United States & international copyright laws. The correct version of this article can be viewed at https://www.watchlistnews.com/mml-investors-services-llc-has-399000-position-in-exact-sciences-co-exas/2667633.html.

About EXACT Sciences

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer.

Recommended Story: Outstanding Shares and The Effect on Share Price

Want to see what other hedge funds are holding EXAS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for EXACT Sciences Co. (NASDAQ:EXAS).

Institutional Ownership by Quarter for EXACT Sciences (NASDAQ:EXAS)

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.